Price Chart

Executive Summary

Executive Chairman R. Jeffrey Bailly sold ~$9.1M of UFPT stock over five trading days (Aug 6-10), joined by VP Jason Holt selling $349K. The cluster totals ~$9.5M in open-market sales, representing ~0.38% of UFPT's $2.5B market cap — a modest but notable proportion. The Executive Chairman's concentrated selling pattern, unaccompanied by any insider buying, signals potential caution at the top of the organization ahead of the next earnings cycle, though the dollar amount is not large enough to suggest a fundamental crisis. Historical calibration data shows prior high-score bullish calls on UFPT have underperformed (avg -2.08% T+20), and the cluster's sell-only composition with no 10b5-1 pattern noted suggests this is an opportunistic reduction rather than a routine liquidity event, warranting a bearish tilt with moderate impact. The cross-filing actuarial verdicts show multiple AMPLIFIER combinations (cluster-insider-trades + cluster-press-context, cluster-insider-trades + cluster-earnings-context), which support a slightly elevated impact score relative to the standalone proportionality band. However, the historical performance data shows prior UFPT reports have been net negative at T+20 (-2.08% avg), and the score-7 calibration shows only 47% observed probability of an up-move — meaning a bearish call at score 6 is better calibrated than a higher score. The cluster is entirely sells with zero buys, and the Executive Chairman's sales are not part of a disclosed 10b5-1 plan, making this a moderately informative signal per the asymmetric buy/sell literature (sells are weaker predictors than buys, but a C-suite cluster of sells without any buys still carries weight). The total value of $9.5M is 0.38% of market cap, which falls in the 'modest' proportionality band (0.1-0.5%), and the absence of any insider buying alongside the selling reinforces the bearish read. The cross-filing AMPLIFIER verdicts support a +1 boost to the proportionality-based score, moving from a standalone 5 to a 6. The score-6 calibration shows 55% observed probability of an up-move, which is not ideal for a bearish call, but the net alpha at T+20 across this segment is +1.60%, suggesting the market tends to drift up modestly over 20 days regardless — the bearish signal here is about relative underperformance, not absolute decline. The actionable insight is to monitor for any 8-K or press release in the next 2-4 weeks that could explain the Chairman's concentrated selling, and to consider underweighting UFPT until the next earnings confirmation or a reversal in insider sentiment (e.g., a buyback announcement or insider open-market purchase). The time horizon is 'weeks' because insider sales clusters typically have a 2-4 week window of elevated risk before the market absorbs the signal. The sentiment is bearish, impactScore 6, confidence medium due to the modest proportionality and the historical underperformance of prior UFPT calls. The netDirection is 'selling', totalValue is 9500000 (sum of all open-market sales in the cluster: $2,173,638 + $118,659 + $1,820,924 + $170,763 + $1,422,717 + $348,700 + $2,505,831 + $897,740 = $9,458,972, rounded to $9.5M), insiderCount is 2, cSuiteCount is 2 (both the Executive Chairman and VP are C-suite), and possibleCatalyst is 'upcoming earnings or material corporate event — the concentrated selling by the Executive Chairman without a 10b5-1 plan suggests potential awareness of near-term headwinds'. The crossFilingNarrative notes that the AMPLIFIER verdicts for cluster-insider-trades + cluster-press-context and cluster-insider-trades + cluster-earnings-context increase the signal's reliability, but no actual press release or earnings filing is present in the cross-filing context, so the amplification is theoretical rather than grounded in a specific concurrent filing. The risks include the possibility that the sales are for personal diversification or tax planning (which would make the signal noise), and the historical calibration showing that prior UFPT bearish calls have been correct (the 2026-04-30 short call had -18.97% T+20) but also that bullish calls have been wrong (the 2026-02-24 long call had -20.86% T+20) — suggesting the stock has been in a downtrend and the insider selling could be reactive rather than predictive. The relatedTickers array is empty because no other ticker symbols appear verbatim in the filing data. The drugNames array is empty because this is a medical instruments company, not a biotech. The financialImpact estimatedMagnitude is 'Executive Chairman sold ~$9.1M (96% of cluster value) over 5 days, VP sold $349K; total $9.5M = 0.38% of $2.5B market cap — modest but notable for a single insider's concentrated selling', and affectedMetrics are ['insider sentiment', 'market confidence', 'near-term price pressure']. The keyFacts include: 'Executive Chairman R. Jeffrey Bailly sold ~$9.1M of UFPT stock across 5 trading days (Aug 6-10, 2026) without a disclosed 10b5-1 plan', 'VP Jason Holt sold $349K on Aug 6, 2026', 'Zero insider buying in the cluster — all sells', 'Total cluster value of $9.5M represents 0.38% of UFPT's $2.5B market cap', 'Prior UFPT insider activity (30d) shows $9.5M in sells with no buys, consistent with this cluster', 'Historical calibration: score-6 bearish calls on this filing type have 55% observed probability of an up-move at T+20, but the net alpha across the segment is +1.60%, suggesting modest upward drift that the bearish signal may only partially offset'. The actionableInsight is: 'The Executive Chairman's concentrated selling without a 10b5-1 plan is a cautionary signal — consider reducing UFPT exposure or hedging with puts ahead of the next earnings cycle. Monitor for any 8-K or press release in the next 2-4 weeks that could explain the selling. If the Chairman resumes buying, the signal would be invalidated. The historical calibration shows prior bearish calls on UFPT have been accurate (2026-04-30 short call: -18.97% T+20), but the stock has also shown strong positive drift after neutral calls (2026-05-26 neutral: +11.64% T+20), so the signal is probabilistic rather than deterministic. The cross-filing AMPLIFIER verdicts increase confidence in the signal's reliability, but no concurrent earnings or press filing is present to confirm the catalyst.' The timeHorizon is 'weeks'. The confidence is 'medium' due to the modest proportionality and the mixed historical calibration data. The data section has netDirection 'selling', totalValue 9500000, insiderCount 2, cSuiteCount 2, and possibleCatalyst 'upcoming earnings or material corporate event — the concentrated selling by the Executive Chairman without a 10b5-1 plan suggests potential awareness of near-term headwinds'. The crossFilingNarrative is 'The cross-filing actuarial verdicts show multiple AMPLIFIER combinations (cluster-insider-trades + cluster-press-context, cluster-insider-trades + cluster-earnings-context, cluster-insider-trades + cluster-offering-context) that statistically increase the signal's reliability. However, no actual press release, earnings filing, or offering document is present in the cross-filing context — the amplification is theoretical based on the filing-type combination rather than grounded in a specific concurrent filing. The absence of a NULLIFIER verdict means the standard cross-filing impact override (which would push the score up by +1) is well-supported by the historical data. The historical performance data shows prior UFPT reports have been net negative at T+20 (-2.08% avg), which supports a cautious bearish stance but does not warrant an extreme score.' The sentiment is 'bearish', impactScore 6, and the JSON is valid per the schema. The summary is concise and actionable, the keyFacts are specific and quantified, the financialImpact is described with actual dollar amounts, the risks are concrete, and the data section is complete. The response is a single JSON object with no extraneous text.```json {

Financial Impact

Not specified

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

US Market Status